Regarding: Humar et al. the efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10:1228-1237

American Journal of Transplantation

Volumn 11, Issue 2, 2011, Pages 408-

  Da Cunha Bang, C ^a   Iversen, M ^a   Mortensen, S A ^a   Rasmussen, A ^a   Sengelov H ^a   Sorensen S S ^a   Lundgren, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cytomegalovirus; prophylaxis; Transplantation; valganciclovir

Indexed keywords

VALGANCICLOVIR;

CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; HIGH RISK POPULATION; INFECTION PREVENTION; INFECTION RISK; KIDNEY GRAFT; LETTER; NONHUMAN; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; RISK FACTORS; TREATMENT OUTCOME;

EID: 79551497497     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03349.x     Document Type: Letter

References (2)

1. Humar A, Lebranchub Y, Vincentic F, et al,. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
2. Scott M Palmer, Ajit P Limaye, Missy Banks, et al,. Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation. A Randomized, Controlled Trial. Ann Intern Med 2010; 152: 761-769.